Amneal Pharmaceuticals (AMRX) Gains from Investment Securities (2021 - 2024)

Amneal Pharmaceuticals' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $930000.0 for Q4 2024.

• On a quarterly basis, Gains from Investment Securities rose 106.78% year-over-year to $930000.0 in Q4 2024; TTM through Sep 2024 was -$14.6 million, a 1117.37% decrease from a year earlier, with the FY2023 full-year figure at -$14.5 million, down 2083.17% from the prior year.
• Gains from Investment Securities rose to $930000.0 in Q4 2024 per AMRX's latest filing, from -$1.0 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $3.1 million in Q3 2023 and bottomed at -$13.7 million in Q4 2023.
• The 4-year median for Gains from Investment Securities is $100000.0 (2024), against an average of -$1.0 million.
• Across the five-year window, Gains from Investment Securities jumped 2326.0% in 2022 and tumbled 2257.04% in 2023, its largest moves.
• Year by year, Gains from Investment Securities stood at -$100000.0 in 2021, then soared by 2326.0% to $2.2 million in 2022, then sank by 715.9% to -$13.7 million in 2023, then surged by 106.78% to $930000.0 in 2024.
• Per Business Quant, the three latest AMRX Gains from Investment Securities figures stand at $930000.0 (Q4 2024), -$1.0 million (Q3 2024), and $100000.0 (Q1 2024).